T he MYC family of transcription factors, comprising MYC, MYCN, and MYCL, includes the most commonly altered oncogenes in cancer 1, 2 . These proteins normally function as master integrators of cellular growth signals and mediate a transcriptional response involved in a variety of processes, including proliferation, cell growth, differentiation, survival, and pluripotency. Amplification of the MYCN oncogene is a characteristic feature of aggressive, relapsed neuroblastoma, an aggressive pediatric cancer arising from neural crest tissue 3, 4 . Targeted MYCN overexpression in peripheral neural crest is sufficient to initiate disease in mouse models 5 . MYCN downregulation broadly reverses tumor stem-like phenotypes 6,7 and aberrant proliferation [8] [9] [10] [11] in a variety of neuroblastoma models [12] [13] [14] , and recent therapeutic strategies to indirectly target MYCN production or protein stability have reduced tumor growth in vivo [15] [16] [17] . Whereas MYCN function has not been dynamically characterized using genome-wide measurements, several recent studies have considered the transcriptional consequences of elevated MYC levels, presenting two seemingly conflicting views on the mechanistic consequences of MYC deregulation in cancer [18] [19] [20] [21] . First, MYC has been reported to function in a context-specific manner, activating or even repressing discrete target genes 20, 21 . Alternatively, MYC has been found to broadly remodel the cancer cis-regulatory landscape, leading to increased transcription at all active genes promoting global transcriptional amplification 18, 19 . At physiological levels, both models predict MYC binding to high-affinity canonical (CACGTG) E-box sites at the promoters of genes involved in growth and proliferation. At deregulated levels, highly abundant MYC proteins, which can only bind to regions of open and accessible chromatin, saturate the cell's active cis-regulatory landscape, binding to prevalent degenerate, non-canonical CANNTG E-boxes (where N represents any base) to effect complex systemic and pleiotropic transcriptional consequences 22 . This is further complicated by the numerous functional roles of MYC family proteins, their complex interaction networks, and the difficulty in discriminating direct effects of MYC binding from secondary, indirect consequences
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To understand the functional consequences of MYCN activation, and to resolve residual ambiguity regarding the mechanisms of genome-wide transcriptional regulation by MYC family transcription factors, we performed kinetic studies of MYCN activation and withdrawal in neuroblastoma.
Results

Deregulated MYCN binds active chromatin and amplifies transcription in neuroblastoma.
To first profile downregulation of MYCN from oncogenic levels, we experimentally selected a panel of human neuroblastoma cell lines with and without MYCN amplification that express varying levels of MYCN ( Fig. 1a and Supplementary Fig. 1a ) and employed the well-characterized tet-off MYCN SHEP-21N cell line model 24 ( Fig. 1b, Supplementary Fig. 1b , and Supplementary Table 1) . Additionally, we explored the consequences of MYCN induction by engineering a tet-on MYCN model in the parental SHEP neuroblastoma cell line grown for multiple passages in a low-MYCN state ( . g, RNA Pol II meta-gene across all active genes upon MYCN shutdown. The regions encompassing the TSS and gene body are enlarged, and significance is indicated. Bottom right, distribution plots of RNA Pol II traveling ratio (TR) for all active genes. Differences in the TR distributions at 0 and 2 h are significant (Welch's two-tailed t test): ***P < 1 × 10
, **P < 1 × 10
. h, mRNA levels of the NPM1 transcript during MYCN shutdown. Units are cell-count-normalized FPKM for triplicate biological replicates. Error bars, s.d. i, Box plots of log 2 fold changes in active gene expression at the indicated time points versus 0 h after MYCN shutdown. Differences between 2 versus 8 h and 4 versus 24 h are significant (Welch's two-tailed t test): **P < 1 × 10
. For all box plots, box and whiskers represent 1 and 2 s.d. from the median (center line).
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Nature GeNetics neuroblastoma lines, we used ChIP-seq to generate a consensus genome-wide map of ~10,000 regions that exhibited strong and consistent MYCN occupancy (Methods and Supplementary Fig. 1c ).
In a deregulated state, MYC binds to virtually all active promoters and subsequently 'invades' promoter-distal enhancer regions 18, 19, 21 . . Bottom, dot plot of the percentage of enhancer contribution (enhancer/total MYCN signal) sampled across bins (100 genes/bin) with a best fit line superimposed (loess correlation). f, Box plots of the log 2 fold change of MYCN load at the TSSs and distal enhancers of the top 5,000 genes ranked by proximal MYCN signal. Top, log 2 fold change at 2 and 24 h (versus 0 h) after MYCN shutdown. Bottom, log 2 fold change at 2 and 6 h (versus 0 h) after MYCN induction. Significance is indicated (Welch's two-tailed t test): ***P < 1 × 10
. g, Cell-count-normalized log 2 fold change (versus 0 h) of gene expression during MYCN shutdown in the SHEP-21N system. Genes are grouped according to rank-ordered MYCN proximal load (promoters and enhancers). Error bars, 95% confidence intervals (CI) of the mean. h, Box plots of the log 2 fold change (versus 0 h) of the amount of RNA Pol II (ChIP-Rx) at the TSS (left) and gene body (right) of genes grouped according to rank-ordered MYCN proximal load. Significance is indicated (Welch's twotailed t test): ***P < 1 × 10 −9
. i, Overall survival of patients ranked by expression (high or low) of the top 25 genes defined by total MYCN load for all patients with neuroblastoma (top) and patients without MYCN amplification (bottom). Significance is indicated as P values from chi-squared tests.
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for example, at NPM1 (Fig. 1d ), which were corroborated by the presence of active transcription marks/factors (H3K4me3, BRD4, RNA polymerase II (Pol II)) in BE(2)-C cells. Genome-wide conserved MYCN-binding regions occurred almost exclusively (96%) at active promoters and enhancers and showed a strong concordance with active chromatin acetylation (H3K27ac), with virtually no overlap with regions of repressive H3K27me3 (Fig. 1e , Methods, and Supplementary Fig. 1d-i) .
We next aimed to characterize the hierarchy of binding at active promoters and enhancers. We found that MYCN signal correlated with H3K27ac signal, and these regions of increased binding overlapped more with active transcriptional start sites (TSSs) versus distal enhancers (Supplementary Fig. 1j ). Trends in MYCN loading are reflected in the underlying sequence composition of binding sites. Strong promoter-associated sites were highly enriched for the canonical (CACGTG) E-box, whereas weaker sites found at promoters and distal enhancers showed higher enrichment of clustered non-canonical (CANNTG) E-boxes ( Fig. 1e and Supplementary  Fig. 1j ). These trends in E-box occupancy were recapitulated by de novo motif discovery at promoters and enhancers (Fig. 1e ) and are consistent with MYCN broadly associating with active regulatory elements in an affinity-dependent manner, as previously observed for MYC 19, 25 . These data support a model that, when deregulated, MYCN binds strongly at canonical E-boxes found at the promoters of active genes (for example, RPL22) and at clustered non-canonical E-boxes found at weaker promoters and distal enhancers (for example, ID2) ( Supplementary Fig. 1d,e) .
We next investigated the dynamic chromatin and transcriptional consequences of direct MYCN depletion. Using the controllable tet-off MYCN SHEP-21N cells, we rapidly and synchronously eliminated MYCN with a 96% reduction achieved after only 6 h (Fig. 1b) . Distinct from previous studies of MYC inactivation, we characterized rapid kinetic effects of dynamic modulation of MYCN (at 0, 2, and 24 h after inactivation) to profile changes in states with high, medium, and low levels of MYCN. In anticipation of global changes to chromatin and transcription that might be masked by relative chromatin enrichment methods, we complemented traditional ChIP-seq methods with the cell-count-normalized ChIP-Rx 26 approach to quantify absolute changes in MYCN, H3K27ac, H3K4me3, CTCF, and RNA Poll II occupancy (Methods and Supplementary Fig. 2a,b) .
We observed that 2 h after shutdown, MYCN was significantly depleted from promoters and enhancers ( Fig. 1f and Supplementary  Fig. 2c ,e,f)-as shown by ChIP-Rx cell count normalization ( Supplementary Fig. 2e ,f). At the exemplary MYC target gene NPM1, loss of MYCN from promoter regions initially resulted in a decrease in elongating RNA Pol II and subsequent loss of NPM1 mRNA, suggesting that MYCN directly promotes transcriptional elongation, again akin to MYC (Fig. 1d,h ). Overall, early defects in transcriptional pause release culminated in loss of active chromatin marks and both initiating and elongating RNA Pol II, resulting in a global dampening of mRNA steady-state levels ( Fig. 1g-i and Supplementary Fig. 2d-j) . Although both traditional ChIP-seq and ChIP-Rx showed global loss of MYCN at promoters and enhancers, we observed global loss of additional marks (H3K4me3, CTCF, H3K27ac, and RNA Pol II) at 24 h after MYCN shutdown only in ChIP-Rx data (Supplementary Figs. 2g and 3a-c). As all ChIP-Rx datasets showed this global effect, in the absence of a negative control, we hypothesize, but cannot conclude with certainty, that MYCN shutdown has global effects on chromatin compaction in neuroblastoma, as has been recently reported for MYC in B cell activation 27 . We do note that, using global H3K27ac quantification, we observed a global loss in chromatin acetylation 24 h after MYCN shutdown ( Supplementary Fig. 2h ), an observation also consistent with previous reports that MYC regulates global chromatin accessibility. In contrast, induction of MYCN in parental SHEP neuroblastoma cells (Fig. 1c,d ) resulted in loading of MYCN at active promoters and enhancers and was coincident with increases in global H3K27ac (Supplementary Fig. 3d-f ). These data are consistent with MYCN acting as a global amplifier of transcription in neuroblastoma.
Enhancer invasion shapes MYCN transcriptional response in neuroblastoma.
To better assess the direct contribution of MYCN to the transcriptional response at individual genes, we hypothesized a direct relationship between underlying MYCN sequence affinity at promoter/enhancer regions, MYCN loading at these regions, and the resulting transcriptional response upon MYCN perturbation (Fig. 2a) . Visual inspection of the MYCN load at highly occupied genes identified a diversity of binding profiles, with some genes exhibiting promoter MYCN binding (RPL22) and others exhibiting a more mixed array of promoter and enhancer binding (HAND2 and ID2) (Fig. 2b) .
As enhancers are highly tissue specific and context dependent, we sought to determine whether similar MYCN enhancer invasion occurs in vivo. Here we profiled MYCN and H3K27ac occupancy in the TH-MYCN genetically engineered mouse model in which a human MYCN transgene is expressed from the tyrosine hydroxylase promoter 5 ( Supplementary Fig. 4a ). We observed MYCN binding at the promoters of classic MYC target genes (Npm1 and Rpl22), as well as at enhancers for key neuroblastoma-and/or neuralcrest-associated genes (Id2 and Gata2) ( Fig. 2c and Supplementary  Fig. 4b ,c). Notably, MYCN binding also occurred at additional enhancers that others have shown to be lineage or tumor specific 28 , such as the Mirlet7b and Lin28 loci, respectively ( Supplementary  Fig. 4d ,e). let-7 is a prominent microRNA (miRNA) tumor suppressor that is often post-transcriptionally attenuated by induction of LIN28 in neuroblastoma 28 . Overall, in human neuroblastoma cell lines conserved MYCN-bound promoters (69%) and enhancers (36%) exhibited evidence of chromatin acetylation (H3K72ac) in TH-MYCN tumors as well as in mouse celiac and superior cervical ganglia (the established tumor tissues of origin that displayed little MYCN activity) ( Supplementary Fig. 4a,f) . Together, these data suggest that deregulated MYCN binds to and invades developmental enhancers that are pre-established. In support of this hypothesis, induced MYCN in SHEP parental cells (cultured over time without MYCN) overwhelmingly bound to and invaded preacetylated promoters and enhancers ( Fig. 2d and Supplementary Fig. 3a,b) .
Globally, genes with the highest total MYCN signal at proximal regulatory loci (promoters and nearby (< 50 kb away) distal enhancers) exhibited a higher contribution of MYCN enhancer occupancy than MYCN promoter occupancy (quantified as MYCN enhancer contribution) (Fig. 2e ). This MYCN loading at enhancers occurred at broad regions with numerous discrete peaks, leading to higher overall levels of MYCN. These data suggest that distal enhancers provide a reservoir for excess MYCN that is only accessed upon deregulation. This MYCN loading at enhancers was observed both for MYCN in SHEP-21N cells and averaged across neuroblastoma cell lines ( Supplementary Fig. 5a,b) . Indeed, 2 and 24 h after MYCN shutdown, weaker MYCN-binding sites at enhancers were preferentially depleted in SHEP-21N cells when compared to promoter sites enriched for canonical E-boxes. Conversely, induction of MYCN resulted in the opposite effect, with promoter sites preferentially gaining MYCN-binding sites ( Fig. 2f and Supplementary  Fig. 3d ). Preferential enhancer loss corresponded to increased transcriptional sensitivity, as measured using both cell-countnormalized and relative profiling of mRNA levels and elongating RNA Pol II density (Fig. 2g,h and Supplementary Fig. 5c-f ). These findings were recapitulated in BE(2)-C cells using JQ1, a BET bromodomain inhibitor that we have previously shown to selectively deplete MYCN in neuroblastoma ( Supplementary Fig. 6 ) 17 . Overall, we observed a strong dose dependence between MYCN signal and transcriptional response suggesting that the MYCN Articles Nature GeNetics affinity of underlying promoter and enhancer regions shapes MYCN-dependent transcriptional amplification in neuroblastoma. Notably, expression of the top 25 most highly loaded and MYCNsensitive genes could accurately stratify overall survival for neuroblastoma in all patients and specifically in patients without evident MYCN amplification, a cohort that is generally considered to have low risk 29 ( Fig. 2i and Supplementary Table 2 ).
Enhancer invasion accounts for tumor-specific MYC/MYCN signatures. Cellular processes and developmental transitions are regulated by cell-type-specific enhancers. The observed enhancer invasion by deregulated MYCN suggests that MYC family transcription factors may act through pre-established enhancers to amplify tissue-specific gene expression 30, 31 . Toward a general explanation, we investigated active enhancer landscapes in the context of both MYCN (neuroblastoma) and MYC (four tumor types) deregulation. We first examined enhancer structure and MYC/MYCN occupancy at canonical tissue-specific genes. In neuroblastoma cell lines, we observed neuroblastoma-specific enhancer activity and coinciding MYCN binding at the enhancer near the gene encoding TH, a neural crest lineage marker 5 , while we observed multiple myeloma-specific enhancer activity and coinciding MYC binding at the enhancer near the gene encoding the plasma lineage factor IRF4 32 . Lastly, at the promoter-dominant gene NPM1, which is active in both tumor types, we observed conserved MYC and MYCN binding in the tumor type in which each was deregulated (Fig. 3a) . 
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To test this hypothesis globally, we ranked the top 5,000 MYCNloaded genes by their relative promoter/distal enhancer MYCN contribution and performed leading edge functional analysis (Fig. 3b-e) . We found that promoter-dominant genes were statistically enriched for the classically defined core MYC target gene set [33] [34] [35] [36] [37] [38] . In contrast, distal-enhancer-dominant genes included key neuroblastoma oncogenes (HAND2 and ID family transcription factors), neural crest markers (TH), and were enriched for known signaling signatures in neuroblastoma including response to tretinoin (retinoic acid), a pro-differentiating agent used clinically to treat high-risk neuroblastoma 39 . Similar analysis comparing MYCN to the enhancer mark H3K27ac in BE(2)-C cells produced distinct promoter/distal enhancer signatures ( Supplementary Fig. 7a-h,k) , suggesting a MYCN-specific pattern of enrichment. Notably, genes on both the promoter-dominant and enhancer-dominant leading edge were capable of stratifying overall survival of patients with neuroblastoma, suggesting that both promoter-and enhancer-dominant genes contain important oncogenic gene expression programs ( Supplementary Fig. 7i ,j and Supplementary Table 2) .
Notably, shutdown of MYCN preferentially depleted distal enhancer gene signatures, whereas induction of MYCN first established promoter gene signatures before distal enhancer gene signatures ( Fig. 3f and Supplementary Fig. 7l ). These data suggest that deregulated MYCN invades enhancers to drive tumor-specific processes in neuroblastoma.
When this same analysis was performed with four additional models of MYC-driven cancer (MYC-amplified small cell lung cancer, IGH/MYC-translocated multiple myeloma, Burkitt lymphoma, and glioblastoma), we again resolved increased enhancer contribution at highly occupied genes ( Supplementary Fig. 8) . Consistent with the tissue-or tumor-specific nature of enhancers, we observed much stronger correlation of MYC promoter binding than that of enhancers (Fig. 3g,h ). Distal enhancer/promoter analysis showed the MYC core target gene set and associated housekeeping gene signatures at the promoter-dominant leading edge were conserved across tumors. However, in contrast to neuroblastoma, distal-enhancer-dominant MYC-bound genes were enriched for their respective tumor-specific pathways, including chromosome 16p13 amplification in small cell lung cancer 40 , chemokine and CD40 signaling in multiple myeloma [41] [42] [43] [44] , Epstein-Barr virus in multiple myeloma and Burkitt lymphoma 45 , and FOXO3 targets in glioblastoma 46 . Notably, chromatin pathways appeared as a MYC/ MYCN-enhancer-regulated signature in multiple tumor contexts 47, 48 ( Fig. 3i) . These data suggest that enhancer invasion can account for the divergent and often puzzling consequences of oncogenic MYC/ MYCN activation and provide an explanation for the tumor-specific oncogenic phenotypes observed upon MYC/MYCN deregulation.
TWIST1 co-occupies enhancers with MYCN and is required for expression of the MYCN enhancer axis. If MYCN enhancer invasion accounts for the tumor-specific consequences of MYCN deregulation, then the transcription factors that establish tissue-specific enhancers likely define MYCN-enhancer-responsive gene expression programs. In any given cell type, a small set of tissue-specific transcription factors are regulated by large clusters of enhancers (socalled super-enhancers), and these super-enhancer-associated transcription factors themselves often occupy the vast majority of active enhancers and super-enhancers as a core regulatory circuit 49, 50 . Thus, an integrated computational analysis of transcription factor motif occupancy at super-enhancers may allow the inference of transcription factors that define enhancer landscapes. We applied a recently reported methodology developed by our laboratory to define the highly interconnected core regulatory circuitry of enhancer-regulating transcription factors 51, 52 ( Supplementary Fig. 9a-d) . The consensus circuitry included several well-established regulators of neuroblastoma identity, including MEIS1, MES2, GATA2, GATA3, PHOX2A, PHOX2B, and HAND2 [53] [54] [55] , that are not present in other unrelated tumor circuitries (Supplementary Fig. 10 ). These data are consistent with recently reported studies identifying at least two distinct cell states as defined by core regulatory circuitries, including an adrenergic/sympathetic noradrenergic cell state and a mesenchymal/neural crest cell state 56, 57 . Specifically, we found that cell lines BE(2)-C, NGP, and KELLY corresponded to the adrenergic/sympathetic noradrenergic state characterized by PHOX2B, PHOX2A, and GATA3 ( Supplementary Fig. 9a,c) . The SHEP-21N line, which was derived from the parental SHEP line, corresponded to the mesenchymal/neural crest cell state and was defined by PRRX1 and members of the AP-1 transcription factor family ( Supplementary  Fig. 9b,c) . From this analysis, we also retrieved the transcription factors TWIST1 and HAND2 across cell lines of both states, which are lineage-specific bHLH transcription factors with a well-established role in promoting tumorigenesis in several human cancers, including neuroblastoma [58] [59] [60] ( Supplementary Fig. 9d ). Because bHLH transcription factors recognize E-box CANNTG motifs, we hypothesized that the clustered non-canonical E-boxes at enhancers invaded by MYCN might be proximally occupied by TWIST1 and HAND2 and that these factors might collaborate to drive oncogenic enhancer-driven transcription. Indeed, highaffinity TWIST1 and HAND2 sites were predicted at > 80% of all MYCN enhancer sites (Fig. 4a) . As TWIST1 has been implicated in MYCN-amplified neuroblastoma 61 , we sought to investigate its role and relationship to MYCN in regulating neuroblastoma enhancer-driven transcription. Performing ChIP-seq for TWIST1 in the SHEP-21N and BE(2)-C lines, we observed strong overlap of MYCN and TWIST1 at enhancers and showed by de novo motif discovery that TWIST1 recognizes a CANNTG E-box similar to enhancer-bound MYCN (Fig. 4b,c) . Inspection of individual MYCN-invaded enhancer loci highlighted spatially proximal colocalization of MYCN and TWIST1 at clustered non-canonical E-box motifs (Fig. 4d) . Unexpectedly, MYCN shutdown broadly depleted genome-bound TWIST1 at 24 h with minimal change in TWIST1 protein levels (Fig. 4e,f) , suggesting an important regulatory link that was further emphasized by the correlative relationship between MYCN loss and TWIST1 at MYCN-TWIST1 co-occupied regions ( Supplementary Fig. 9e ). Overall, genes with proximal and strong MYCN-TWIST1-occupied enhancers were more potently downregulated by MYCN shutdown than genes associated with only strong MYCN-occupired enhancers (Fig. 4g) . Finally, these genes with high MYCN-TWIST1 occupancy also stratified patients by overall survival (Fig. 4h and Supplementary Table 2 ), implicating the MYCN-TWIST1-regulated gene expression program in neuroblastoma.
As a regulator of mesenchymal lineage and the dedifferentiated cell state in tumors, TWIST1 specifies target genes but relies on other cues, including potentially MYCN, to enforce transcriptional activation or repression. To evaluate TWIST1 as a deregulated MYCN-specific neuroblastoma dependency, we used CRISPR-Cas9, siRNA, and shRNA genetic approaches to perturb TWIST1. First, CRISPR-Cas9 mutagenesis scanning of the TWIST1 locus and its large proximal enhancers with a multiplexed library of 3,351 single guide RNAs (sgRNAs) identified TWIST1 cis-regulatory enhancer elements as required for neuroblastoma proliferation (Fig. 4i,j and Supplementary Table 3 )-a result not seen with similar CRISPR-Cas9 scanning of the expressed chromatin regulator NSD1 ( Supplementary Fig. 9f ,g and Supplementary Table 4 ). These data provide initial validation for the essentiality of cis-regulatory enhancers participating in the predicted neuroblastoma core regulatory circuitry. Second, siRNA depletion of TWIST1 identified a MYCN-dependent effect in neuroblastoma, as seen across cell lines with high (BE(2)-C) versus low (SH-SY5Y) MYCN, and in the isogenic SHEP-21N system at high and low MYCN states ( Supplementary Fig. 9h 
HAND2
Promoter Enh. 4 Enh. 5 Identifying TFs that co-occupy enhancers with MYCN TWIST1 protein levels . f, Cropped western blots of vinculin, MYCN, and TWIST1 levels upon MYCN shutdown. g, Cellcount-normalized log 2 fold change (versus 0 h) of gene expression during MYCN shutdown in the SHEP-21N system. Genes are grouped by MYCN and/or TWIST1 binding: MYCN and TWIST1 co-bound sites (red), MYCN highly bound sites alone (black), and MYCN and TWIST1 lowly co-bound sites (gray). Error bars, 95% CI. h, Overall survival of patients ranked by expression (high or low) of genes highly loaded with MYCN and TWIST1 in all patients with neuroblastoma (left) and those without MYCN amplification (right). Significance was determined by chi-squared tests and P values are shown. i, CRISPRCas9 scan of the TWIST1 locus and its downstream enhancers. Top, Illumina sequencing readout of log 2 fold enrichment/depletion (early versus late time point) of 3,351 sgRNAs. Bottom, simple moving average of log 2 fold enrichment/depletion. j, ChIP-seq signal of H3K27ac (blue), ATAC-seq (green), MYCN (red), and TWIST1 (orange) at the TWIST1 locus and enhancers with respect to CRISPR sgRNAs. Red-shaded boxes highlight regions of marked log 2 fold depletion. k, Top, cropped western blots of vinculin, MYCN, and TWIST1 levels upon TWIST1 knockdown. Bottom, viable cell counts at 3 and 7 d after inducible TWIST1 knockdown. Error bars, s.d. from three biological replicates. l, log 2 fold change (versus 0 h) of gene expression upon TWIST1 knockdown of genes ranked by MYCN promoter load (top) or MYCN distal enhancer load (bottom). Error bars, 95% CI.
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and Supplementary Table 4) . Finally, induced shRNA-mediated kinetic TWIST1 knockdown reduced neuroblastoma proliferation in BE(2)-C cells (Fig. 4k and Supplementary Table 3) , selectively downregulating only genes with high MYCN enhancer signal and failing to downregulate genes with high MYCN promoter loading (Fig. 4l) . This observation is in contrast to MYCN shutdown, which preferentially downregulated genes ranked by either promoter or enhancer MYCN signal (Supplementary Fig. 9j ). These data establish TWIST1 as a key regulator of the MYCN enhancer axis and suggest a potent oncogenic collaboration between TWIST1 and MYCN in driving enhancer-dependent neuroblastoma gene expression.
Discussion
When deregulated, MYCN dominates the active cis-regulatory landscape of neuroblastoma to enforce both proliferation through promoter binding and dedifferentiation through enhancer invasion. We establish that MYCN load at promoters and proximal enhancers predicts transcriptional responsiveness to MYCN shutdown and that MYCN enhancer binding occurs prominently at the most strongly occupied and downregulated genes, suggesting a role for these tissue-specific elements in determining MYCN-responsive 'target' genes.
In neuroblastoma, oncogenic collaboration of MYCN and TWIST1 at enhancers demarcates a set of developmental genes important to neuroblastoma tumorigenesis and highly sensitive to both MYCN and TWIST1 perturbation. In contrast, in the B cell malignancies multiple myeloma and Burkitt lymphoma that do not express HAND or TWIST factors, we instead identify and validate TCF3 (E2A) as a bHLH transcription factor that is selectively required for growth of MYC-deregulated multiple myeloma and may have an equivalent role to TWIST1 ( Supplementary Fig. 10 and Supplementary Table 5 ). These data highlight the extensibility of an approach to identify unrecognized tumor dependencies among core regulatory transcription factors, via collaborative gene control with MYC family oncoproteins.
Finally, instead of focusing only on the overall global transcriptional consequences of MYCN shutdown, or more narrowly on the most differentially regulated target genes, our results prompt a more quantitative consideration of MYCN as a dose-dependent amplifier of transcription that is shaped by E-box-rich cis-regulatory elements at promoters and enhancers. Whereas highly MYC/ MYCN-bound promoters are active in a majority of cell types, the enhancer-dominant MYC/MYCN-bound genes vary greatly between tumor types, suggesting that enhancers and the factors that form them are responsible for imparting gene selectivity and producing the often divergent and tumor-specific MYC/MYCN responses 62 . Notably, highly MYCN-loaded genes stratify patients by overall survival, an effect that is improved by incorporating the MYCN enhancer axis. Interestingly, this gene set is able to stratify patients without genomic MYCN amplification, a cohort with typically favorable prognosis for which there are few means to reliably identify high-risk individuals. Additionally, these data suggest that certain neuroblastoma tumors without MYCN deregulation are able to activate this oncogenic gene expression program. These data provide molecular characterization of the direct MYCN-occupied gene expression program and its role in patient disease progression.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-018-0044-9.
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Methods
Cell lines. SK-N-AS, SH-SY5Y, NGP, BE(2)-C, and KELLY cells were kindly provided by K. Stegmaier (Dana-Farber Cancer Institute) and cultured in DMEM supplemented with 10% FBS. SHEP-21N cells were kindly provided by W. Weiss (University of California, San Francisco) and cultured in RPMI supplemented with 10% tetracycline-free FBS (Clontech). SHEP-TetOn_MYCN cells were lentivirally engineered (the parental SHEP line was kindly provided by W. Weiss) and cultured in identical conditions to the SHEP-21N cells. BE(2)-C_shTWIST1,2 cells were lentivirally engineered and cultured in DMEM supplemented with 10% tetracycline-free FBS. Controllable expression in each respective system was performed by addition of doxycycline (0.2-0.5 μ g/ml) to the growth medium. The multiple myeloma cell lines MM.1S and U266 were purchased from American Type Culture Collection (ATCC) and cultured in RPMI supplemented with 10% FBS. All cell lines were tested for mycoplasma using the MycoAlert kit (Lonza, LT07-218) following the manufacturer's instructions. Immunoblotting. For whole-cell lysates, cells were lysed using RIPA buffer supplemented with protease inhibitor cocktail (Roche) for 20 min. Lysates were clarified at 16,000g for 15 min at 4 °C, and protein concentration was determined by BCA assay (Pierce). For cell-count-normalized blots, cell numbers were determined using the Countess automated cell counter (Invitrogen) before RIPA lysis. A histone extraction was performed for histone blots on cell-countnormalized pellets by acid extraction. Cells were lysed in Triton Extraction Buffer followed by an overnight acid extraction in 0.2 N HCl. Antibodies for western blotting were purchased as follows: MYCN (Santa Cruz, sc-56729), vinculin (Santa Cruz, sc-25336), GAPDH (Cell Signaling, 2118), H3K27ac (Abcam, ab4729), histone H3 (Cell Signaling, 3638), and TWIST1 (Abcam, ab50887). Blots were imaged using fluorescence-labeled secondary antibodies (LI-COR) on the OdysseyCLX Imager (LI-COR). All western blots are shown as cropped images, with full scans of blots provided with molecular weight/size markers labeled in Supplementary Figs. 11 and 12. RNA isolation. Prior to RNA isolation, cell numbers were determined using the Countess automated cell counter (Invitrogen). Total RNA isolation was performed using the miRvana miRNA total RNA isolation kit (Thermo Fisher Scientific, AM1560) according to the manufacturer's instructions. Following isolation, RNA was digested with DNase (Ambion). During isolation, external RNA spike-ins (ERCC, Ambion) were added at the time of cell lysis. Total RNA was subjected to poly(A) selection and adaptor ligation in preparation for next-generation sequencing (Illumina stranded mRNA library prep) on NextSeq (75-bp, single-end reads).
Cell
siRNA transfection. Neuroblastoma cells were reverse transfected (Lipofectamine RNAiMAX, Invitrogen) with 40 nM of individual siRNA duplexes (Dharmacon). Protein knockdown was assessed 48 h after transfection, and viable cell count measurements were made 72 h after transfection using the Countess automated cell counter (Invitrogen) in biological triplicates.
qRT-PCR analysis. Expression of the human TCF3 transcript was determined using real-time qRT-PCR based on the TaqMan fluorescence methodology, following the manufacturer's protocols (Applied Biosystems). The GAPDH gene was used as a housekeeping gene control. Relative expression was calculated using the comparative Δ Δ Ct method.
Cell proliferation, viability, and apoptosis assays. Multiple myeloma cell proliferation was measured by ( 3 H)thymidine uptake incorporation assay following the manufacturer's instructions (PerkinElmer). Cell viability was analyzed by CellTiter-Glo (CTG) following the manufacturer's instructions (Promega). Apoptosis was evaluated by flow cytometric analysis following annexin V (PE) and DAPI staining.
RNA cell count microarray expression analysis. Biotinylated RNA was prepared according to the standard Affymetrix protocol from 100 ng of total RNA. Following fragmentation, 12.5 μ g of RNA was hybridized at 45 °C for 16 h at 60 r.p.m. on GeneChip arrays (PrimeView). GeneChips were washed and stained in the Affymetrix Fluidics Station 450 according to the manufacturer's instructions, using the buffers provided in the Affymetrix GeneChip hybridization, wash and stain kit. GeneChips were scanned using the GeneChip Scanner 3000, and images were extracted with the Affymetrix GeneChip Expression Console. Immunohistochemistry. Paraformaldehyde-fixed mouse tumor and ganglia tissues were processed for immunohistochemistry using standard methods. Tissue specimens were subjected to heat-induced epitope retrieval using citrate buffer (pH 6). The M.O.M. kit (Vector Laboratories) was used to minimize non-specific labeling. Tissues were stained with a MYCN antibody (OP13, Calbiochem) followed by a biotinylated mouse secondary antibody (M.O.M. kit). Stained specimens were developed using ImmunoPACT substrate (Vector Laboratories) and counterstained with hematoxylin. After counterstaining, specimens were dehydrated, cleared, and mounted using DPX mountant.
TH-MYCN
Survival analysis of patients with neuroblastoma.
Matched patient outcome and expression data were obtained for 425 patients from Oberthuer et al. 64 . To link expression of various gene sets to overall survival, we first identified genes with expression data present in the dataset of Oberthuer et al. Across samples, expression values were rank transformed and the median rank of the gene set was used to stratify patients into high (top 5th percentile) and low (bottom 5th percentile) cohorts. Kaplan-Meier curves were generated using the R package survival and a KM plotting script authored by A. Dasgupta (see URLs). The statistical significance of the difference between the Kaplan-Meier curves was tested using a chi-squared test with P values reported. This analysis was applied for four gene sets: the top 1,000 genes ranked by total (enhancer + promoter) MYCN load (Fig. 2i) , the top 1,000 genes ranked by either promoter dominance or enhancer dominance ( Supplementary Fig. 7i,j) , and the top TWIST1-+ MYCNoccupied genes (Fig. 4h) . Analysis was applied to either all patients with neuroblastoma (n = 22 each in the high and low cohorts) or to those specifically without MYCN genomic amplification (n = 19 each in the high and low cohorts). ChIP. ChIP was performed as described 65 with minor changes. Neuroblastoma cell lines were grown to 75% confluence in 15-cm plates and cross-linked with 1% formaldehyde (10 min) followed by quenching (125 mM glycine). Cells were washed in cold PBS and harvested by cell scraper in cold PBS with protease inhibitors (Roche). Cells were centrifuged at 1,650g for 5 min and flash frozen and stored at -80 °C at 5 × 10 6 cells per pellet. Pellets were resuspended in cytosolic and then nuclear lysis buffer, and DNA was sheared at 4 °C using a water-bath sonicator (Bioruptor, Diagenode) for 25 min at high output (30 s on, 30 s off) in 1 ml of sonication buffer supplemented with 0.5% SDS. Sonicated lysates were cleared by centrifuging at 20,000g for 10 min and incubated overnight end over end at 4 °C with magnetic beads prebound with antibody. Beads were washed three times with sonication buffer, one time with sonication buffer with 500 mM NaCl added, once with LiCl wash buffer (20 mM Tris pH 8.0, 1 mM EDTA, 250 mM LiCl, 0.5% NP-40, 0.5% sodium deoxycholate), and once with TE. DNA was eluted in elution buffer (50 mM Tris-HCl pH 8, 10 mM EDTA, and 1% SDS). Cross-links were reversed overnight at 65 °C. RNA and protein were digested with 0.2 mg/ml RNase A for 2 h followed by 0.2 mg/ml proteinase K for 1 h. DNA was purified with phenol chloroform extraction and ethanol precipitation. Figure 1 describes the cohort of neuroblastoma cells (n=4) and the analysis used to determine that this n was sufficient to identify consensus MYCN bi nding sites in the genome.
Data exclusions
Describe any data exclusions.
No inclusion/exclusion criteria were used
Replication
Describe whether the experimental findings were reliably reproduced.
Experimental data was run in biological triplicate wherever feasible. ChIP-seq data sets were replicated with ChIP-Rx datasets. MYCN inducible seq datasets were produced in both a tet-on and tet-off state to replicate findings.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
No randomization was used.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
No blinding was applied
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code 7. Software
Describe the software used to analyze the data in this study.
Sequencing data was analyzed using publically available and custom code (python based) and visualized using R. Western blot data was analyzed (bands quantified) using the LiCor ImageStudio software. Functional data was analyzed and graphed in GraphPad PRISM.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
All unique materials are available upon request.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
All antibodies with catalog numbers are provided in the experimental methods und er sections "immunoblotting" and "Chromatin immunoprecipitation (ChIP)". Study did not involve human research participants
